HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

Benzinga Newsdesk www.benzinga.com Negative 54.3%

Neg 54.3% Neu 0% Pos 0%

HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.